What Country (Other Than The U.S.) Will Have The Biggest Impact On Biopharma In The Next Three To Five Years?

A: HAVING WORKED IN PHARMA in the EU, U.S., emerging markets, and Japan, I have found outstanding research and a passion for patients in each of these geographies. Most impressive are the international networks of collaboration and the exchange of ideas that happen between countries. In our business, we must seek scientific excellence wherever it is, oblivious to borders and stripped of preconceptions. Indeed, funding from biopharma is often essential in countries where there are less academic resources. From Glasgow to Hyderabad, there is a desire to replicate the dense clusters of biotech found in Boston and San Francisco with a mixture of biotech, pharma, and academia encouraging cross talk between industry and academia and a fertilization of ideas.

SANDY MACRAE, M.B., CH.B., PH.D.
Sandy is CEO of Sangamo Therapeutics. He has over 20 years of leadership experience in the pharmaceutical industry.